in cardiovascular medicine
ESC publishes guidelines for use of new oral anticoagulant drugs with atrium fibrillation
The European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) has published a practical guide on the use of new oral anticoagulants (NOACs). The document summarises existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make clear what the similarities and differences are.
Companies provide a Summary of Product Characteristics (SmPC) for their drug but the content is bound by legal restrictions. The current EHRA guide is more specific than the SmPCs and provides expert guidance on what to do in specific clinical situations. The EHRA worked in close collaboration with the drug companies to ensure that all of the information in the SmPCs is also in the guide.
Fifteen clinical scenarios are given with practical information on how to handle them. The clinical situations include how to initiate and monitor NOAC use, how to measure the anticoagulant effect if needed in specific situations, switching between anticoagulants, ensuring compliance, patients with chronic kidney disease and management of bleeding complications.
ESC guidelines on atrial fibrillation recommend the NOACs as preferable to vitamin K-antagonists for stroke prevention in patients with non-valvular atrial fibrillation.
Unlike vitamin K-antagonists, NOACs do not require regular monitoring of anticoagulation level. Since the novel anticoagulant drugs have a very short half-life, patients are not protected when they stop taking the drug. Therefore, suggestions are given on how to improve compliance.
Furthermore, the document advises how to switch safely from a vitamin K-antagonist to a NOAC. The bleeding risk profile of the NOACs is better than that of vitamin K-antagonists. But bleedings will occur, so the practical document also outlines what action should be taken in the event of bleeding.
“Like all new drugs, also NOACs have pitfalls. Physicians who follow the practical advices in this guide will improve the safety of their patients,” according to Professor S. Hohnloser, who is a reviewer of the EHRA guide and member of the ESC atrial fibrillation guidelines task force.
The full guide ‘NOAC for AF’, an executive summary and print-ready patient cards can be found on
: press release of ESC 26 April 2013
Rivaroxaban reduces thrombotic events after STEMI
6-5-2013 • Mega JL, Braunwald E, Murphy SA, et al.
Results from the ATLAS ACS-2-TIMI-51 trial show that rivaroxaban reduced cardiovascular events in patients with a recent STEMI
Systematic review of NOACs next to antiplatelet therapy after ACS
22-3-2013 • Oldgren J, Wallentin L, Alexander JH et al.
Treatment with NOACs next to antiplatelet therapy after acute coronary syndrome slightly reduces adverse cardiovascular events but increases clinically significant bleeding.
FDA Fast Track designation for investigational anticoagulant reversal agent
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to facilitate the development and expedite the review of PER977, an agent that directly reverses normal coagulation
Clinically guided dose lowering of FXa-inhibitor can optimise risk-benefit balance of anticoagulation
23-3-2015 • Ruff CT et al., Lancet. 2015
Analysis of ENGAGE AF-TIMI 48 shows that the efficacy of edoxaban as compared with warfarin is preserved when the dose is reduced based on clinical features, without routine monitoring of drug concentration or anticoagulant activity.
Increase in events after apixaban discontinuation likely due to initiation of VKA therapy
4-2-2015 • Granger CB et al., Am Heart J. 2015
The increased risk of stroke/SE and bleedings seen at the end of the ARISTOTLE trial appears to be the result achieving stable INR with VKA, rather than that stopping apixaban per se increases risk.
Andexanet alfa immediately reverses anticoagulation effect of rivaroxaban
Phase III ANNEXA-R study tested the efficacy and safety of a universal antidote to factor Xa inhibitors in healthy volunteers. Primary endpoint was met and andexanet alfa was well tolerated.
ESC advises heart disease patients to reduce exposure to air pollution from traffic
A position paper regards air pollution as a modifiable disease risk factor, and gives recommendations on how exposure to air pollution can be reduced.
Small molecule quickly reverses anticoagulant activity of edoxaban
PER977 stably restored baseline haemostasis within 10-30 minutes after anticoagulant administration in healthy volunteers. This reversal agent binds to all NOACs.
Treating elderly AF patients with anticoagulation improves survival, more so than antiplatelets
23-10-2014 • Wändell PE et al., Age Ageing. 2014
Men and women with AF aged
75 years show increased survival with anticoagulants as compared to no treatment or treatment with antiplatelets. Not all pharmaceutical groups were associated with lower mortality and some sex differences were observed.
Amiodarone use together with warfarin increases risk of stroke/SE and lowers TTR
15-10-2014 • Flaker G et al., J Am Coll Cardiol. 2014
Substudy of ARISTOTLE shows that apixaban consistently reduced the rate of stroke and SE, death and major bleeding when compared with warfarin, whether patients received amiodarone or not.
GDF-15 levels may improve risk assessment for bleeding and mortality in AF
14-10-2014 • Wallentin L et al., Circulation. 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, improves risk stratification for bleeding and mortality beyond clinical risk factors in anticoagulated patients with AF
Positive results with antidote for Factor Xa inhibitor
The first Phase 3 study of Factor Xa inhibitor antidote andexanet alfa, met its primary and secondary endpoints and shows well-tolerated and effective reversal of anticoagulation activity of apixaban.
© 2009 - 2015 PACE - Physicians's Academy for Continuing Education -